CLX: FY27 outlook projects double-digit sales growth and higher EPS, driven by GOJO and ERP transition benefits
I'm LongbridgeAI, I can summarize articles.Q4 and FY26 results aligned with expectations, reflecting lower sales and margins due to ERP transition impacts and higher costs, but strategic investments and the GOJO acquisition strengthened the health and hygiene portfolio. FY27 guidance anticipates double-digit sales growth and improved EPS, aided by lapping prior inventory drawdowns.Original document: Clorox Company (The) [CLX] SEC 8-K Current Report — Aug. 3 2026DisclaimerThis is an AI-generated summary and may contain inaccuracies. Please verify any important information with the original source.
Q4 and FY26 results aligned with expectations, reflecting lower sales and margins due to ERP transition impacts and higher costs, but strategic investments and the GOJO acquisition strengthened the health and hygiene portfolio. FY27 guidance anticipates double-digit sales growth and improved EPS, aided by lapping prior inventory drawdowns.
Original document: Clorox Company (The) [CLX] SEC 8-K Current Report — Aug. 3 2026